Carregant...
Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial
BACKGROUND: Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA). The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an important regulator of osteoclast activity and bone resorption and is associate...
Guardat en:
| Publicat a: | BMC Musculoskelet Disord |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4841945/ https://ncbi.nlm.nih.gov/pubmed/27108405 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-016-1036-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|